Updated Analysis of Nivolumab Plus Ipilimumab Combos Highlights Long OS for Advanced Melanoma

Source: Cancer Network, March 2022

The 6.5-year updated analysis of the phase 3 CheckMate 067 trial highlighted notable overall survival benefit with nivolumab alone or in combination with ipilimumab for patients with advanced melanoma.

Patients with advanced melanoma experienced durable melanoma-specific survival (MSS) and a long median overall survival (OS) following treatment with nivolumab (Opdivo) alone or in combination with ipilimumab (Yervoy), according to data from the phase 3 CheckMate 067 trial (NCT01844505) published in the Journal of Clinical Oncology.

After a median follow-up of 6.5 months, the median OS was 72.1 months in the nivolumab plus ipilimumab group, 36.9 months in the nivolumab group, and 19.9 months for ipilimumab group. Additionally, the median MSS was not reached, 58.7 months, and 21.9 months in each group, respectively. The 6.5-year OS rate was 57.0%, 43.0%, and 25.0% for patients with BRAF-mutant tumors, and 46.0%, 42.0%, and 22.0% for BRAF wild-type tumors in the combination, nivolumab, and ipilimumab groups, respectively.

READ THE ORIGINAL FULL ARTICLE